Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following ...
Fulcrum Therapeutics Inc. FULC shares are up on Thursday as the company faces significant challenges following its decision ...
Fulcrum Therapeutics said today it is scrapping its lead pipeline program to develop pociredir as a treatment for sickle cell ...
Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class.
Abstract HighlightsRinzimetostat is a potent and highly selective next-generation allosteric PRC2 inhibitor targeting the EED subunit that has demonstrated potential best-in-class efficacy and safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results